脂肪移植重建手术对年轻乳腺癌女性预后的影响:法国保险数据库研究
该研究基于法国国家医疗保健系统数据库,纳入2010年1月1日至2018年12月31日期间18至45岁非转移性乳腺癌患者共50178例,比较脂肪移植与其他重建技术对生存的影响。乳房切除组中脂肪移植与更好的无病生存(HR 0.76,95%CI 0.65-0.88)和总生存相关,肿块切除组无显著差异。作者认为脂肪移植可作为安全的乳房切除后重建选择,但需进一步研究确认。
要点
- 乳房切除组脂肪移植与其他重建相比,无病生存HR 0.76(95%CI 0.65-0.88)。
- 乳房切除组脂肪移植与无任何重建相比,无病生存HR 0.59(95%CI 0.51-0.69)。
- 肿块切除组脂肪移植与对照相比,无病生存和总生存均无显著差异。
核心结论
- 作者认为脂肪移植似乎改善接受乳房切除(伴或不伴额外重建)的年轻女性的生存结局。
- 肿块切除组未观察到显著影响,脂肪移植可作为安全的乳房切除后重建选择,但需进一步研究确认结果并理解潜在机制。
研究设计与样本
- 基于法国国家医疗保健系统数据库的匹配分析,纳入2010年1月1日至2018年12月31日期间18至45岁非转移性乳腺癌患者50178例。
- 脂肪移植组与其他重建组按乳腺癌亚型、化疗、放疗及乳腺癌术后重建时机进行匹配,分析按乳房切除术或肿块切除术分层。
主要发现
- 共纳入50178例患者:管腔型肿瘤28260例,三阴性乳腺癌7982例,HER2阳性肿瘤7087例,未定义肿瘤6849例。
- 乳房切除组7333例、肿块切除组883例接受脂肪移植。
- 乳房切除组匹配后,脂肪移植与其他重建相比,无病生存更好(HR 0.76,95%CI 0.65-0.88),总生存也更好。
- 乳房切除组脂肪移植与无任何重建相比,无病生存更好(HR 0.59,95%CI 0.51-0.69)。
- 肿块切除组无病生存和总生存均无显著差异。
关键数值与推荐
- 乳房切除组脂肪移植 vs 其他重建:无病生存HR 0.76(95%CI 0.65-0.88)。
- 乳房切除组脂肪移植 vs 无任何重建:无病生存HR 0.59(95%CI 0.51-0.69)。
- 证据等级:治疗性,III级。
临床怎么用
- 作者认为脂肪移植可作为安全的乳房切除后重建选择,尤其适用于乳房切除术后。
- 作者指出需进一步研究确认这些结果并理解潜在机制。
局限性
- 作者指出需进一步研究确认这些结果并理解潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fat grafting (FG) is widely used in breast reconstructive surgery (RS) after mastectomy or lumpectomy for breast cancer (BC); however, concerns persist about its oncologic safety. This study evaluated the impact of FG reconstruction compared with other techniques on BC survival in young women. METHODS: The authors identified patients aged 18 to 45 years treated for nonmetastatic BC in the French National Healthcare System Database between January 1, 2010, and December 31, 2018. Patients undergoing FG were matched with patients undergoing other RS on the basis of BC subtype, chemotherapy, radiotherapy, and RS timing after BC surgery. Analyses were stratified on breast surgery (mastectomy or lumpectomy). RESULTS: A total of 50,178 patients were included: 28,260 with luminal tumors, 7982 with triple-negative BC, 7087 with HER2-positive tumors, and 6849 with undefined tumors. In the mastectomy and lumpectomy group, 7333 and 883 patients, respectively, received FG. In the mastectomy group, after matching, FG was associated with better disease-free survival (DFS) (hazard ratio, 0.76 [95% CI, 0.65 to 0.88]) and overall survival compared with patients with other RS. FG also showed improved DFS (hazard ratio, 0.59 [95% CI, 0.51 to 0.69]) compared with patients without any RS. No significant differences in DFS or overall survival were found in the lumpectomy group. CONCLUSIONS: FG appears to improve survival outcomes in young women undergoing mastectomy with or without additional RS. In contrast, no significant impact was observed in the lumpectomy group. These findings suggest that FG can be a safe reconstructive option, particularly after mastectomy. Further research is needed to confirm these results and understand the underlying mechanisms. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Laas E, Gaillard T, Couturaud B, et al. The Impact of Fat Graft Reconstructive Surgery on Prognosis in Young Women with Breast Cancer: A Study from the French Insurance Databases. Plast Reconstr Surg. 2025. PMID: 40178525. doi:10.1097/PRS.0000000000012120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。